Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US30161Q1040
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BL3220
EXEL
Exelixis Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Exelixis Inc
ISIN
US30161Q1040
TICKER
EXEL
MIC
XNAS
REUTERS
EXEL.OQ
BLOOMBERG
EXEL US
Di., 03.11.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:Guggenheim 3rd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, November 10 in Boston.Stifel 2026 Healthcare Conference: Exelix...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 29.10.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continued to execute across all of our key priorities in the third quarter, driving the caboza...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 15.10.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be av...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 14.10.2026       Exelixis
US30161Q1040

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The pace of new treatments has picked up with it: about 150 new a...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 14.10.2026       Exelixis
US30161Q1040

SAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The pace of new treatments has picked up with it: about 150 new active s...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 13.10.2026       Exelixis
US30161Q1040

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance ref...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Tuesday, September 8 in Boston. Citi 2026 Biopharma Back to School Conf...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mo., 31.08.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District o...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Exelixis
US30161Q1040

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance ref...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Exelixis
US30161Q1040

Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating. NEW YORK, Aug. 17, 2026 /PRNewswire/ -- A revenue miss, not an earnings miss, drove Exelixis, Inc. (NASDAQ: EXEL) shares lower after the Company reported app...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 17.08.2026       Exelixis
US30161Q1040

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or “the Company”) (NASDAQ: EXEL) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 12.08.2026       Exelixis
US30161Q1040

Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact J...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 11.08.2026       Exelixis
US30161Q1040

Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of EXEL shareholders. NEW YORK, Aug. 11, 2026 /PRNewswire/ -- A reduced full-year 2026 revenue outlook...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 11.08.2026       Exelixis
US30161Q1040

On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell. NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) reiterated its full-year 2026 financial guidance on its May 5, 2026 earnings call. Following its second qu...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 05.08.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continues to execute across the key pillars of our business, positioning the company to deliv...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 22.07.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be ava...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Sa., 30.05.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 11:05 a.m. ET / 8:05 a.m. PT on Wednesday, June 3 in New York City. Goldman Sachs 47th Annual Global Healthcar...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago. “The presentations at ASCO this year highlight the conti...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 19.05.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in combination with zanzalintinib in STELLAR-316, a...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026: Exelixis is scheduled to present at 1:00 p.m. ET / 10:00 a.m. PT on Tuesday, May 12 in Las Vegas. 2026 RBC Capital Markets Global Healthcare Confer...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis made significant progress in the first quarter of 2026 as we remain focused on our goal of bui...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference: Exelixis is scheduled to present at 1:10 p.m. ET / 10:10 a.m. PT on Tuesday, March 3 in Boston. Leerink Partners 2026 Global Healthcare Conferenc...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Exelixis
US30161Q1040

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 24, 2026 /CNW/ -- USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion in 2026 to an estimated $748.17 billion by 2035[1]. Cancer drug revenues alone are projected to reach $335.2 billion by...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Exelixis
US30161Q1040

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 24, 2026 /PRNewswire/ -- USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion in 2026 to an estimated $748.17 billion by 2035[1]. Cancer drug revenues alone are projected to reach $335.2 bill...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis delivered strong results in 2025 and is well positioned for a breakout year i...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinoteca...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 27.01.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
So., 11.01.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozanti...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 07.01.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis’ novel oral kinase inhibitor, with and without an immune checkpoint in...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 06.01.2026       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET. To access the webcast link, log onto www.exelixis.com and proceed to the E...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 03.12.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis’ R&D activities and outline the company’s strat...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference:...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on cr...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Exelixis
US30161Q1040

NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 23.10.2025       Exelixis
US30161Q1040

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 21.10.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mo., 20.10.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the stud...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Sa., 18.10.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical On...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Sa., 13.09.2025       Exelixis
US30161Q1040

NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mo., 08.09.2025       Exelixis
US30161Q1040

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Exelixis
US30161Q1040

LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or "the Company") (NASDAQ: EXEL) for violations of the securities laws....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Exelixis
US30161Q1040

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or “the Company”) (NASDAQ: EXEL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Fr., 29.08.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company’s drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Ex...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Exelixis
US30161Q1040

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: 2025 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 12:45 p.m. ET / 9:45 a.m. PT on Wednesday, September 3 in Everett, MA. Citi’s 2025 Biopharma Back to School Co...
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Exelixis
US30161Q1040

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Fr., 22.08.2025       Exelixis
US30161Q1040

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink
Sa., 16.08.2025       Exelixis
US30161Q1040

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Exelixis
Charts & Research Termsheets Terminal
Permalink